Deferasirox (Exjade®) for the treatment of iron overload

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalActa Haematologica
Volume122
Issue number2-3
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Iron Overload
Iron
Anemia
Therapeutics
Chelation Therapy
Aptitude
Thalassemia
Hemochromatosis
Aplastic Anemia
Poisons
Myelodysplastic Syndromes
Sickle Cell Anemia
Patient Compliance
Ferritins
Chelating Agents
deferasirox
Pediatrics
Liver
Serum

Keywords

  • Chelation
  • Deferasirox
  • Myelodysplastic syndromes
  • Pediatric anemia
  • Sickle cell disease
  • Thalassemia

ASJC Scopus subject areas

  • Hematology

Cite this

Deferasirox (Exjade®) for the treatment of iron overload. / Cappellini, M. D.; Taher, A.

In: Acta Haematologica, Vol. 122, No. 2-3, 11.2009, p. 165-173.

Research output: Contribution to journalArticle

@article{8304acfe25864a57999736926c4ae58e,
title = "Deferasirox (Exjade{\circledR}) for the treatment of iron overload",
abstract = "Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.",
keywords = "Chelation, Deferasirox, Myelodysplastic syndromes, Pediatric anemia, Sickle cell disease, Thalassemia",
author = "Cappellini, {M. D.} and A. Taher",
year = "2009",
month = "11",
doi = "10.1159/000243801",
language = "English",
volume = "122",
pages = "165--173",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Deferasirox (Exjade®) for the treatment of iron overload

AU - Cappellini, M. D.

AU - Taher, A.

PY - 2009/11

Y1 - 2009/11

N2 - Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.

AB - Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.

KW - Chelation

KW - Deferasirox

KW - Myelodysplastic syndromes

KW - Pediatric anemia

KW - Sickle cell disease

KW - Thalassemia

UR - http://www.scopus.com/inward/record.url?scp=70450219836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450219836&partnerID=8YFLogxK

U2 - 10.1159/000243801

DO - 10.1159/000243801

M3 - Article

C2 - 19907154

AN - SCOPUS:70450219836

VL - 122

SP - 165

EP - 173

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2-3

ER -